TrovaGene Inc (NASDAQ:TROV) shares traded up 2.8% during trading on Monday . The company traded as high as $0.38 and last traded at $0.37. 970,383 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 1,985,277 shares. The stock had previously closed at $0.36.
A number of research analysts have recently commented on the company. downgraded TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $1.00 price objective on shares of TrovaGene in a report on Tuesday, March 6th. Maxim Group reiterated a “hold” rating on shares of TrovaGene in a report on Monday, March 5th. Finally, ValuEngine upgraded TrovaGene from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. TrovaGene currently has an average rating of “Hold” and a consensus price target of $4.33.
TrovaGene (NASDAQ:TROV) last released its quarterly earnings data on Monday, February 26th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. TrovaGene had a negative return on equity of 315.63% and a negative net margin of 4,932.08%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million. analysts expect that TrovaGene Inc will post -0.26 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “TrovaGene (TROV) Trading 2.8% Higher” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3262133/trovagene-trov-trading-2-8-higher.html.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.